Literature DB >> 22451309

Antemortem pulse pressure elevation predicts cerebrovascular disease in autopsy-confirmed Alzheimer's disease.

Daniel A Nation1, Lisa Delano-Wood, Katherine J Bangen, Christina E Wierenga, Amy J Jak, Lawrence A Hansen, Douglas R Galasko, David P Salmon, Mark W Bondi.   

Abstract

Elevated pulse pressure (PP) is associated with cognitive decline and increased risk of Alzheimer's disease (AD) in older adults, although the mechanisms behind these associations remain unclear. To address this question, we examined whether antemortem late-life PP elevation predicted vascular or AD pathology in autopsy-confirmed AD patients. Sixty-five elderly patients (mean age 74.2 years) clinically diagnosed with possible or probable AD underwent neuropsychological testing and blood pressure examinations. Postmortem histopathological measures of cerebrovascular disease (CVD) and AD neuropathology were later obtained on these same patients. We expected that antemortem PP elevation, but not standard blood pressure measures such as systolic or diastolic blood pressure, would predict the autopsy-based presence of CVD, and possibly AD pathology, in elderly AD patients. Results demonstrated that antemortem PP elevation was associated with the presence and severity of CVD at autopsy. For every 5 mmHg increase in antemortem PP there was an estimated 36% increase in the odds of having CVD at autopsy. Additionally, PP accounted for 12% of variance in CVD severity. No significant associations were present for cerebral amyloid angiopathy or Braak and Braak staging of the severity of AD pathology. Other standard blood pressure measures also did not significantly predict neuropathology. The association between antemortem PP and CVD at autopsy suggests that in older adults with AD, PP elevation may increase the risk of CVD. These findings may have treatment implications since some antihypertensive medications specifically address the pulsatile component of blood pressure (e.g., renin-angiotensin system inhibitors, calcium channel blockers).

Entities:  

Mesh:

Year:  2012        PMID: 22451309      PMCID: PMC3370943          DOI: 10.3233/JAD-2012-111697

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  31 in total

1.  Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study.

Authors:  H Petrovitch; L R White; G Izmirilian; G W Ross; R J Havlik; W Markesbery; J Nelson; D G Davis; J Hardman; D J Foley; L J Launer
Journal:  Neurobiol Aging       Date:  2000 Jan-Feb       Impact factor: 4.673

Review 2.  Antihypertensive therapy and de-stiffening of the arteries.

Authors:  Michel E Safar; Piotr Jankowski
Journal:  Expert Opin Pharmacother       Date:  2010-11       Impact factor: 3.889

3.  Placebo-controlled trials of blood pressure-lowering therapies for primary prevention of dementia.

Authors:  Jan A Staessen; Lutgarde Thijs; Tom Richart; Augustine N Odili; Willem H Birkenhäger
Journal:  Hypertension       Date:  2010-12-28       Impact factor: 10.190

Review 4.  Antihypertensive treatments, cognitive decline, and dementia.

Authors:  Emmanuelle Duron; Olivier Hanon
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

5.  Elevated pulse pressure is associated with age-related decline in language ability.

Authors:  D A Nation; C E Wierenga; L Delano-Wood; A J Jak; D C Delis; D P Salmon; M W Bondi
Journal:  J Int Neuropsychol Soc       Date:  2010-07-21       Impact factor: 2.892

6.  A rapid and sensitive PCR strategy employed for amplification and sequencing of porA from a single colony-forming unit of Neisseria meningitidis.

Authors:  N B Saunders; W D Zollinger; V B Rao
Journal:  Gene       Date:  1993-12-31       Impact factor: 3.688

7.  Pulse pressure and pulse wave velocity are related to cognitive decline in the Baltimore Longitudinal Study of Aging.

Authors:  Shari R Waldstein; S Carrington Rice; Julian F Thayer; Samer S Najjar; Angelo Scuteri; Alan B Zonderman
Journal:  Hypertension       Date:  2007-11-19       Impact factor: 10.190

Review 8.  The pulsatile component of blood pressure: its role in the pathogenesis of atherosclerosis.

Authors:  Piotr Jankowski; Grzegorz Bilo; Kalina Kawecka-Jaszcz
Journal:  Blood Press       Date:  2007       Impact factor: 2.835

Review 9.  Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage.

Authors:  Gary F Mitchell
Journal:  J Appl Physiol (1985)       Date:  2008-09-04

10.  Cerebrovascular Pathology Contributes to the Heterogeneity of Alzheimer's Disease.

Authors:  Dannie Etiene; Joanny Kraft; Neema Ganju; Teresa Gomez-Isla; Brad Gemelli; Bradley T. Hyman; E. Tessa Hedley-Whyte; Jack R. Wands; Suzanne M. De La Monte
Journal:  J Alzheimers Dis       Date:  1998-12       Impact factor: 4.472

View more
  21 in total

1.  Neuropsychological Deficit Profiles, Vascular Risk Factors, and Neuropathological Findings in Hispanic Older Adults with Autopsy-Confirmed Alzheimer's Disease.

Authors:  Gali H Weissberger; Tamar H Gollan; Mark W Bondi; Daniel A Nation; Lawrence A Hansen; Douglas Galasko; David P Salmon
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

2.  Cortical and subcortical cerebrovascular resistance index in mild cognitive impairment and Alzheimer's disease.

Authors:  Daniel A Nation; Christina E Wierenga; Lindsay R Clark; Sheena I Dev; Nikki H Stricker; Amy J Jak; David P Salmon; Lisa Delano-Wood; Katherine J Bangen; Robert A Rissman; Thomas T Liu; Mark W Bondi
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

3.  Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer's disease.

Authors:  Katherine J Bangen; Daniel A Nation; Lisa Delano-Wood; Gali H Weissberger; Lawrence A Hansen; Douglas R Galasko; David P Salmon; Mark W Bondi
Journal:  Alzheimers Dement       Date:  2014-07-09       Impact factor: 21.566

Review 4.  Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association.

Authors:  Costantino Iadecola; Kristine Yaffe; José Biller; Lisa C Bratzke; Frank M Faraci; Philip B Gorelick; Martha Gulati; Hooman Kamel; David S Knopman; Lenore J Launer; Jane S Saczynski; Sudha Seshadri; Adina Zeki Al Hazzouri
Journal:  Hypertension       Date:  2016-10-10       Impact factor: 10.190

5.  Elevated Markers of Vascular Remodeling and Arterial Stiffness Are Associated With Neurocognitive Function in Older HIV+ Adults on Suppressive Antiretroviral Therapy.

Authors:  Jessica L Montoya; Jennifer Iudicello; Pariya L Fazeli; Suzi Hong; Michael Potter; Ronald J Ellis; Igor Grant; Scott L Letendre; David J Moore
Journal:  J Acquir Immune Defic Syndr       Date:  2017-02-01       Impact factor: 3.731

6.  Assessing intracranial vascular compliance using dynamic arterial spin labeling.

Authors:  Lirong Yan; Collin Y Liu; Robert X Smith; Mayank Jog; Michael Langham; Kate Krasileva; Yufen Chen; John M Ringman; Danny J J Wang
Journal:  Neuroimage       Date:  2015-09-10       Impact factor: 6.556

Review 7.  Hypertension and Its Role in Cognitive Function: Current Evidence and Challenges for the Future.

Authors:  Timothy M Hughes; Kaycee M Sink
Journal:  Am J Hypertens       Date:  2015-11-11       Impact factor: 2.689

8.  Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.

Authors:  Belinda Yew; Daniel A Nation
Journal:  Brain       Date:  2017-07-01       Impact factor: 13.501

9.  Late-Life Vascular Risk Factors and Alzheimer Disease Neuropathology in Individuals with Normal Cognition.

Authors:  Lilah M Besser; Michael L Alosco; Liliana Ramirez Gomez; Xiao-Hua Zhou; Ann C McKee; Robert A Stern; John Gunstad; Julie A Schneider; Helena Chui; Walter A Kukull
Journal:  J Neuropathol Exp Neurol       Date:  2016-08-11       Impact factor: 3.685

10.  Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults.

Authors:  Daniel A Nation; Steven D Edland; Mark W Bondi; David P Salmon; Lisa Delano-Wood; Elaine R Peskind; Joseph F Quinn; Douglas R Galasko
Journal:  Neurology       Date:  2013-11-13       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.